CA3180215A1 - Dual-agonist compound for both glp-1 and gip receptors and application thereof - Google Patents

Dual-agonist compound for both glp-1 and gip receptors and application thereof

Info

Publication number
CA3180215A1
CA3180215A1 CA3180215A CA3180215A CA3180215A1 CA 3180215 A1 CA3180215 A1 CA 3180215A1 CA 3180215 A CA3180215 A CA 3180215A CA 3180215 A CA3180215 A CA 3180215A CA 3180215 A1 CA3180215 A1 CA 3180215A1
Authority
CA
Canada
Prior art keywords
amino acid
acid residue
group
acid residues
oeg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3180215A
Other languages
English (en)
French (fr)
Inventor
Fangzhou WU
Lei Wang
Xuchao Huang
Ran WU
Renzhi Liu
Haiqing Hua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tuo Jie Biopharmaceutical Co Ltd
Original Assignee
Beijing Tuo Jie Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuo Jie Biopharmaceutical Co Ltd filed Critical Beijing Tuo Jie Biopharmaceutical Co Ltd
Publication of CA3180215A1 publication Critical patent/CA3180215A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3180215A 2020-05-29 2021-05-28 Dual-agonist compound for both glp-1 and gip receptors and application thereof Pending CA3180215A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010472577.8 2020-05-29
CN202010472577 2020-05-29
CN202110335100 2021-03-29
CN202110335100.X 2021-03-29
PCT/CN2021/096568 WO2021239082A1 (zh) 2020-05-29 2021-05-28 Glp-1和gip受体双重激动剂化合物及其应用

Publications (1)

Publication Number Publication Date
CA3180215A1 true CA3180215A1 (en) 2021-12-02

Family

ID=78745631

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3180215A Pending CA3180215A1 (en) 2020-05-29 2021-05-28 Dual-agonist compound for both glp-1 and gip receptors and application thereof

Country Status (11)

Country Link
US (1) US20230190879A1 (https=)
EP (1) EP4159750A4 (https=)
JP (1) JP2023526973A (https=)
KR (1) KR20230018395A (https=)
CN (3) CN114222755B (https=)
AU (1) AU2021278157A1 (https=)
BR (1) BR112022023834A2 (https=)
CA (1) CA3180215A1 (https=)
MX (1) MX2022014368A (https=)
TW (1) TWI910174B (https=)
WO (1) WO2021239082A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
US20250115654A1 (en) * 2021-11-12 2025-04-10 Fujian Shengdi Pharmaceutical Co., Ltd. Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
WO2023207106A1 (zh) * 2022-04-29 2023-11-02 苏州星洲生物科技有限公司 Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
EP4556487A1 (en) * 2022-07-13 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1/gip dual agonist, and preparation method therefor and use thereof
CN115806593B (zh) * 2022-09-23 2023-09-05 成都普康生物科技有限公司 一种脂肪酸链修饰的双受体激动剂及其用途
CN116120425A (zh) * 2022-12-27 2023-05-16 南京赛诺生物技术有限公司 一种glp-1/gip受体双重激动剂及其应用
CN118056839B (zh) * 2023-01-17 2024-11-29 广东众生睿创生物科技有限公司 带有修饰结构的多肽及其应用
CN118684758A (zh) * 2023-03-23 2024-09-24 上海民为生物技术有限公司 肠促胰岛素类似物及其应用
CN116496361B (zh) * 2023-06-25 2023-09-15 北京科翔中升医药科技有限公司 氘代模拟肽gip和glp-1双受体激动剂药物及用途
TW202529797A (zh) * 2023-12-12 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
WO2025242218A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 一种多肽激动剂，其制备方法及医药用途
CN120081924A (zh) * 2024-07-11 2025-06-03 中国药科大学 Glp-1r受体激动多肽化合物及其用途
CN119390784A (zh) * 2024-07-11 2025-02-07 中国药科大学 一种双激动多肽化合物及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6006118B2 (ja) * 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
US9453062B2 (en) * 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
CN104583232B (zh) * 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
AU2013366692B2 (en) * 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
CN108271356A (zh) * 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
CN107108715A (zh) * 2014-10-24 2017-08-29 默沙东公司 胰高血糖素和glp‑1受体的共激动剂
WO2016131893A1 (en) * 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
US10946074B2 (en) * 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
CN112351994B (zh) * 2019-04-11 2024-06-07 江苏豪森药业集团有限公司 一种多受体激动剂及其医药用途
CN111825758B (zh) * 2019-04-19 2024-11-22 上海翰森生物医药科技有限公司 Glp-1和gip共激动剂化合物

Also Published As

Publication number Publication date
CN118530333A (zh) 2024-08-23
MX2022014368A (es) 2022-12-15
EP4159750A1 (en) 2023-04-05
JP2023526973A (ja) 2023-06-26
TW202144393A (zh) 2021-12-01
AU2021278157A1 (en) 2022-11-24
WO2021239082A1 (zh) 2021-12-02
CN114222755B (zh) 2024-06-11
US20230190879A1 (en) 2023-06-22
CN118754965A (zh) 2024-10-11
CN114222755A (zh) 2022-03-22
BR112022023834A2 (pt) 2022-12-27
TWI910174B (zh) 2026-01-01
EP4159750A4 (en) 2023-10-18
KR20230018395A (ko) 2023-02-07

Similar Documents

Publication Publication Date Title
CA3180215A1 (en) Dual-agonist compound for both glp-1 and gip receptors and application thereof
CN112351994B (zh) 一种多受体激动剂及其医药用途
CN113383014B (zh) 双受体重激动剂化合物及其药物组合物
US20250115654A1 (en) Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
US20260055155A1 (en) Incretin analog and use thereof
TW202502808A (zh) Glp-1、gip和gcg受體三激動劑及其應用
RU2848325C1 (ru) Соединение с двойной агонистической активностью в отношении рецепторов glp-1 и gip и его применение
RU2816492C2 (ru) Мультирецепторный агонист и его медицинское применение
HK40069563B (zh) Glp-1和gip受体双重激动剂化合物及其应用
HK40069563A (en) Dual-agonist compound for both glp-1 and gip receptors and application thereof
EA053272B1 (ru) Фармацевтическая композиция двойного агониста рецептора glp-1 и рецептора gip и ее применение
HK40051504A (en) Dual receptor-acting agonist compounds and pharmaceutical composition thereof
HK40043112A (en) Multi-receptor agonist and medical use thereof
AU2026202757A1 (en) Multi-receptor agonist and medical use thereof
CA3286784A1 (en) Incretin analog and use thereof
HK40043112B (zh) 一种多受体激动剂及其医药用途
HK40051504B (zh) 双受体重激动剂化合物及其药物组合物

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250724

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250724

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260203

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260204